Últimas noticias sobre Teleflex (NYSE:TFX) Bolsa

TELEFLEX INC

Teleflex

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

Teleflex Inc

Teleflex Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow&#x2122; Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey.
Key highlights include:
<ul>
<li>The pre-specified CVC subgroup analysis evaluated the impact of Chlorhexidine-impregnated CVCs on CLABSI rates using CLABSI rates per 1,000 CL (central-line)-days.</li>
<li>70.5% reduction in the incidence of CLABSI in patients with Arrowg+ard Blue&#x2122; and Arrowg+ard Blue Plus&#x2122; CVCs vs. plain (non-impregnated) catheters.</li>
<li>Lower incidence of infection-causing pathogens with Chlorhexidine-impregnated CVCs, including gram-negative and gram-positive bacteria and fungi.</li>
<li>Insertion training and the use of maximal barrier precautions were similar across both groups, eliminating technique variability as a confounding factor.</li>
<li>Use of an unprotected CVC may be an independent risk factor for CLABSI when compared to patients with Chlorhexidine-impregnated CVCs. &nbsp;</li>
</ul>
The study's CVC analysis demonstrated a statistically significant reduction in CLABSIs of 70.5% in patients receiving the impregnated antimicrobial catheters. These patients had longer average length of ICU stay and device utilization ratios, indicating frequent and extended use. Despite this, infection remained significantly lower, underscoring the potential benefit of the antimicrobial technology even in high-risk patients. Acknowledging potential variations in patients and characteristics across study hospitals and the lack of a metric (e.g., Standard Infection Ratio) to adjust for these factors in the countries in the study, the authors noted that the study data nonetheless provides "significant evidence" regarding impregnated CVCs.

News

Teleflex Catheters Cut ICU Infection Risk by Over 70%, Study Finds in 6-Country Trial

Teleflex Reports Titan SGS Stapler Associated With Lower Post-Operative GERD Rates In 7-Year Retrospective Study Of Robotic Sleeve Gastrectomy Patients

On May 7, Duncan, Board Member at Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), executed a strategic insider move by acquiring stock options for 0 shares.
What Happened: Uncovered in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000096943/000009694325000079//Archives/edgar/data/96943/000009694325000079/0000096943-25-000079-index.htm">U.S. Securities and Exchange Commission</a>, Duncan, Board Member at Teleflex, executed an insider options move. This move consisted of acquiring stock options for 0 shares of TFX, granting Duncan the right to purchase the company's stock at an exercise price of $0.0 per share.
As of Thursday morning, Teleflex shares are up by 0.18%, with a current price of $122.3. This implies that Duncan's 0 shares have a value of $0.
<h3>About Teleflex</h3>
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
<h3>Key Indicators: Teleflex's Financial Health</h3>
Revenue Growth: Teleflex's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -5.04%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 55.58%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Teleflex's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 2.08.
</li>
</ul>
Debt Management: Teleflex's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.49.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 37.8 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 1.9 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 12.58 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000096943">Check Out The Full List Of Teleflex's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

C. Duncan Takes A Bullish Stance, Acquiring Teleflex Stock Options Worth $0

Teleflex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has fallen 37.05% since its last report. The company recently reported that it has 1.56 million shares sold short, which is 5.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746536547_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teleflex has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 4.10%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Teleflex?

Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and lowers the price target from $140 to $137.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Teleflex, Lowers Price Target to $137

Morgan Stanley analyst Patrick Wood maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Overweight and lowers the price target from $191 to $173.

Morgan Stanley Maintains Overweight on Teleflex, Lowers Price Target to $173

RBC Capital analyst Shagun Singh maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Sector Perform and lowers the price target from $150 to $145.

RBC Capital Maintains Sector Perform on Teleflex, Lowers Price Target to $145

Wells Fargo analyst Larry Biegelsen maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Equal-Weight and lowers the price target from $146 to $137.

Wells Fargo Maintains Equal-Weight on Teleflex, Lowers Price Target to $137

WIIM

Teleflex shares are trading lower after the company reported Q1 financial results and cut its FY25 adjusted EPS guidance below estimates. Also, the company announced it expects an impact from tariffs.

Guidance

For 2025, Teleflex Says 'We expect an impact from tariffs of approximately $55 million in 2025, which will be recorded in cost of goods sold. We are currently evaluating mitigation strategies to reduce this exposure'

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) lowers FY2025 Adj EPS guidance from $13.95-$14.35 to $13.20-$13.60 vs $14.13 analyst estimate..

Teleflex Lowers FY2025 Adj EPS Guidance from $13.95-$14.35 to $13.20-$13.60 vs $14.13 Est

Earnings

Earnings Beats

Teleflex Q1 Adj. EPS $2.91 Beats $2.87 Estimate, Sales $700.70M Beat $699.32M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

The QuikClot Control+ Device was previously indicated for temporary control of class III and class IV internal organ space bleeding, severely bleeding surgical wounds, mild and moderate bleeding in cardiac surgical procedures, and bone surfaces following sternotomy.

Health Care

General

The FDA Has Granted 510(k) Clearance Of An Expansion To The Indications For Use Of Teleflex's QuikClot Control+ Hemostatic Device To Include All Grades Of Internal And External Bleeding

Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and lowers the price target from $149 to $140.

Truist Securities Maintains Hold on Teleflex, Lowers Price Target to $140

Teleflex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has risen 116.84% since its last report. The company recently reported that it has 2.42 million shares sold short, which is 8.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743685231_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teleflex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 4.23%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Teleflex?

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Teleflex, revealing an average target of $153.2, a high estimate of $191.00, and a low estimate of $140.00. Observing a downward trend, the current average is 35.03% lower than the prior average price target of $235.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1743616859_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Teleflex by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$191.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$140.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$149.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$146.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teleflex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teleflex compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Teleflex's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teleflex's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TFX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teleflex analyst ratings.</a>
<h2>Delving into Teleflex's Background</h2>
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
<h3>A Deep Dive into Teleflex's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Teleflex showcased positive performance, achieving a revenue growth rate of 2.78% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teleflex's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -17.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Teleflex's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -3.12%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teleflex's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.87%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Teleflex's debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Teleflex: What You Need To Know

Citizens Capital Markets analyst David Turkaly reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Market Perform to Market Perform.

Reiteration

Citizens Capital Markets Reiterates Market Perform on Teleflexto Market Perform

Teleflex Receives FDA 510(k) Clearance Of The AC3 Range Intra-Aortic Balloon Pump (IABP)

<ul>
<li>The Ringer&#x2122; PBC study is a limited prospective, multi-center, single-arm IDE study, undertaken at four sites in the United States investigating the Ringer&#x2122;&nbsp;PBC for the management of emergent coronary perforations that develop during percutaneous coronary intervention (PCI) procedures. The study enrolled 30 participants, and analysis was performed based upon intention-to-treat. The primary efficacy endpoint required successful Ringer&#x2122; PBC delivery and inflation at the perforation site, control of extravasation (defined as residual Ellis grade 0 or 1), and preservation of antegrade coronary flow (Thrombolysis in Myocardial Infarction [TIMI] grade 2 or 3).</li>
<li>Of 30 participants enrolled, the primary efficacy endpoint was observed in 22 participants (73.3%), with successful Ringer&#x2122;&nbsp;PBC delivery in 26 participants (86.7%). Among those participants with successful delivery, control of extravasation with perfusion was achieved in 22 participants (84.6%). Twelve participants were treated with a covered stent following perforation management with the Ringer&#x2122;&nbsp;PBC. One participant required emergency surgery for complications of pericardiocentesis, and three participants died despite control of extravasation from the index perforation.</li>
</ul>

Teleflex Announced That The Preliminary Results From Its Ringer PBC IDE Study Were Reported In A Featured Presentation At The CTO Plus Conference

Press Releases

Teleflex Investor News: Rosen Law Firm Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX

Dividends

Teleflex Announces Quarterly Dividend

New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy

Teleflex Showcases New Clinical Data Presented at the 2025 American Urological Association (AUA) Annual Meeting

Teleflex Publishes 2024 Global Impact Report

Legal

Teleflex Incorporated Announcement: If You Have Suffered Losses in Teleflex Incorporated (NYSE: TFX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men's Health Month

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients

Comments

Teleflex

Noticias

Últimas noticias sobre Teleflex (NYSE:TFX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL